Suppr超能文献

肺部炎症期间过氧化物酶体增殖物激活受体-α表达的调控

Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation.

作者信息

Becker Julien, Delayre-Orthez Carine, Frossard Nelly, Pons Françoise

机构信息

EA3771 Inflammation et environnement dans l'asthme, Faculté de Pharmacie, Université Louis Pasteur-Strasbourg I, 74 route du rhin, BP 60024, 67401 Illkirch, France.

出版信息

Pulm Pharmacol Ther. 2008;21(2):324-30. doi: 10.1016/j.pupt.2007.08.001. Epub 2007 Aug 21.

Abstract

Peroxisome proliferator-activated receptor-alpha (PPARalpha) is implicated in the control of airway inflammation. However, little is known so far about PPARalpha expression and regulation in the lung. Our aim was to assess PPARalpha expression in the lung from normal mice, as well as to investigate its regulation during airway inflammation or in response to anti-inflammatory agents. The PPARalpha activator, fenofibrate, the glucocorticoid, dexamethasone or vehicle was administered to normal mice, to mice exposed to tumor necrosis factor-alpha (TNF-alpha) or lipopolysaccharide (LPS) or to ovalbumin (OVA)-sensitized and challenged animals. PPARalpha expression was assessed by quantifying PPARalpha mRNA levels using real-time quantitative PCR after reverse-transcription of total lung RNA. Airway inflammation was evaluated by determining total and differential cell counts, as well as TNF-alpha production in bronchoalveolar lavage fluids. PPARalpha mRNA was found at significant levels in the lung from normal mice. This expression was increased by 65% (p<0.05) and 55% (p<0.05) in animals treated with fenofibrate and dexamethasone, respectively. In mice exposed to TNF-alpha or LPS, as well as in animals sensitized and challenged with OVA, that exhibited airway inflammation, PPARalpha mRNA was decreased by 60% (p<0.05), 43% (p<0.05) and 50% (p<0.05), respectively. In mice exposed to LPS, down-regulation of PPARalpha was maximal at 4h, whereas TNF-alpha production and cell infiltration peaked at 2 and 24h, respectively. In the lung of mice exposed to LPS or OVA and treated with fenofibrate or dexamethasone, PPARalpha down-regulation was suppressed, while airway inflammation was abolished. Our data showed that PPARalpha is constitutively expressed in mouse lung and down-regulated in response to TNF-alpha or upon acute or allergic airway inflammation. Fenofibrate and dexamethasone upregulated PPARalpha in normal lung and suppressed PPARalpha down-regulation associated with airway inflammation. Taken together, our data show that PPARalpha expression is inversely regulated with lung inflammation.

摘要

过氧化物酶体增殖物激活受体α(PPARα)与气道炎症的控制有关。然而,迄今为止,关于PPARα在肺中的表达和调控知之甚少。我们的目的是评估正常小鼠肺中PPARα的表达,并研究其在气道炎症期间或对抗炎药物反应中的调控。将PPARα激动剂非诺贝特、糖皮质激素地塞米松或赋形剂给予正常小鼠、暴露于肿瘤坏死因子α(TNF-α)或脂多糖(LPS)的小鼠或卵清蛋白(OVA)致敏并激发的动物。通过对全肺RNA进行逆转录后使用实时定量PCR定量PPARα mRNA水平来评估PPARα的表达。通过测定支气管肺泡灌洗液中的总细胞计数和分类细胞计数以及TNF-α的产生来评估气道炎症。在正常小鼠的肺中发现PPARα mRNA处于显著水平。在用非诺贝特和地塞米松处理的动物中,这种表达分别增加了65%(p<0.05)和55%(p<0.05)。在暴露于TNF-α或LPS的小鼠以及用OVA致敏并激发的表现出气道炎症的动物中,PPARα mRNA分别降低了60%(p<0.05)、43%(p<0.05)和50%(p<0.05)。在暴露于LPS的小鼠中,PPARα的下调在4小时时最大,而TNF-α的产生和细胞浸润分别在2小时和24小时达到峰值。在暴露于LPS或OVA并用地非诺贝特或地塞米松处理的小鼠肺中,PPARα的下调受到抑制,而气道炎症被消除。我们的数据表明,PPARα在小鼠肺中组成性表达,并在对TNF-α或急性或过敏性气道炎症反应时下调。非诺贝特和地塞米松上调正常肺中的PPARα,并抑制与气道炎症相关的PPARα下调。综上所述,我们的数据表明PPARα的表达与肺部炎症呈负调控。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验